{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:03:00Z","timestamp":1789639380483,"version":"4.0.0"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jaut.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T18:18:01Z","timestamp":1477073881000},"page":"10-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":173,"special_numbering":"C","title":["The antiphospholipid syndrome in patients with systemic lupus erythematosus"],"prefix":"10.1016","volume":"76","author":[{"given":"Guillermo J.","family":"Pons-Estel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-3218","authenticated-orcid":false,"given":"Laura","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Scanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Tincani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2016.10.004_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2014.01.006","article-title":"Diagnosis and classification of the antiphospholipid syndrome","volume":"48\u201349","author":"Gomez-Puerta","year":"2014","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.10.004_bib2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/bmj.287.6399.1088","article-title":"Thrombosis, abortion, cerebral disease, and the lupus anticoagulant","volume":"287","author":"Hughes","year":"1983","journal-title":"Br. Med. J. Clin. Res. Ed."},{"key":"10.1016\/j.jaut.2016.10.004_bib3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib4","doi-asserted-by":"crossref","first-page":"A299","DOI":"10.1016\/j.autrev.2009.11.013","article-title":"The geoepidemiology of the antiphospholipid antibody syndrome","volume":"9","author":"Biggioggero","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.004_bib5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2007.11.011","article-title":"Lessons from the \u201cEuro-Phospholipid\u201d project","volume":"7","author":"Cervera","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.004_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.semarthrit.2011.05.007","article-title":"HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies","volume":"41","author":"Appenzeller","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11926-009-0010-8","article-title":"Neonatal effects of maternal antiphospholipid syndrome","volume":"11","author":"Tincani","year":"2009","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2016.10.004_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.10.004_bib9","first-page":"285","article-title":"The anticardiolipin syndrome","volume":"3","author":"Hughes","year":"1985","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/ard.48.5.362","article-title":"Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder","volume":"48","author":"Mackworth-Young","year":"1989","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib11","first-page":"1742","article-title":"A\u00a0\u201cprimary\u201d antiphospholipid syndrome?","volume":"15","author":"Asherson","year":"1988","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib12","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/art.21224","article-title":"Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups","volume":"52","author":"Mok","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archinte.164.1.77","article-title":"High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus","volume":"164","author":"Ruiz-Irastorza","year":"2004","journal-title":"Arch. Intern Med."},{"key":"10.1016\/j.jaut.2016.10.004_bib15","first-page":"2214","article-title":"Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis","volume":"33","author":"Opatrny","year":"2006","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.md.0000172074.53583.ea","article-title":"Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?","volume":"84","author":"Gomez-Puerta","year":"2005","journal-title":"Med. Baltim."},{"key":"10.1016\/j.jaut.2016.10.004_bib17","first-page":"1589","article-title":"Primary antiphospholipid syndrome evolving into systemic lupus erythematosus","volume":"22","author":"Mujic","year":"1995","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib19","doi-asserted-by":"crossref","first-page":"A277","DOI":"10.1016\/j.autrev.2009.12.008","article-title":"The geoepidemiology of systemic lupus erythematosus","volume":"9","author":"Borchers","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.004_bib20","first-page":"46","article-title":"Survival and prognostic factors of death risk in antiphospholipid syndrome: results of 8-year follow-up","volume":"75","author":"Reshetniak","year":"2003","journal-title":"Ter. Arkh"},{"key":"10.1016\/j.jaut.2016.10.004_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Med. Baltim."},{"key":"10.1016\/j.jaut.2016.10.004_bib22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib23","first-page":"1522","article-title":"A\u00a0review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value?","volume":"34","author":"Bobba","year":"2007","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib24","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib25","first-page":"1802","article-title":"Exclusion criteria for primary antiphospholipid syndrome","volume":"20","author":"Piette","year":"1993","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.thromres.2004.06.045","article-title":"Inflammatory response and the endothelium","volume":"114","author":"Meroni","year":"2004","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jaut.2016.10.004_bib27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.10.004_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11926-010-0149-3","article-title":"Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?","volume":"13","author":"Barbhaiya","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2016.10.004_bib29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1538-7836.2005.01295.x","article-title":"A\u00a0prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis","volume":"3","author":"Forastiero","year":"2005","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.10.004_bib30","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood-2007-01-066043","article-title":"Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study","volume":"110","author":"Galli","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2016.10.004_bib31","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2016.10.004_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.10.004_bib33","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2002-11-3334","article-title":"Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome","volume":"102","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2016.10.004_bib34","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2016.10.004_bib35","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0961203307083316","article-title":"Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus","volume":"16","author":"Martinez-Berriotxoa","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.10.004_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0961203310395053","article-title":"Antiphospholipid syndrome clinical research task force report","volume":"20","author":"Erkan","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.10.004_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11926-013-0405-4","article-title":"Management of recurrent thrombosis in antiphospholipid syndrome","volume":"16","author":"Nalli","year":"2014","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2016.10.004_bib38","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3899\/jrheum.150983","article-title":"Modified framingham risk factor score for systemic lupus erythematosus","volume":"43","author":"Urowitz","year":"2016","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib39","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/art.33340","article-title":"Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events","volume":"64","author":"Otomo","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib40","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the global anti-phospholipid syndrome score","volume":"52","author":"Sciascia","year":"2013","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2016.10.004_bib41","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","article-title":"A\u00a0risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score","volume":"8","author":"Barbar","year":"2010","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.10.004_bib42","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/kei142","article-title":"'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus","volume":"44","author":"Bruce","year":"2005","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2016.10.004_bib43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.autrev.2011.10.014","article-title":"Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: \u201cPros\u201d and \u201cCons\u201d","volume":"11","author":"Ceccarelli","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.004_bib44","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1001\/archinte.160.13.2042","article-title":"Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis","volume":"160","author":"Wahl","year":"2000","journal-title":"Arch. Intern Med."},{"key":"10.1016\/j.jaut.2016.10.004_bib45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2013.10.014","article-title":"Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis","volume":"13","author":"Arnaud","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.004_bib46","first-page":"S17","article-title":"Mortality and malignancy in the multi-ethnic Birmingham lupus cohort aspirin use is beneficial and non-Caucasian origin is not associated with poor outcome","volume":"41","author":"Leung","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2016.10.004_bib47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ket313","article-title":"Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)","volume":"53","author":"Cuadrado","year":"2014","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2016.10.004_bib48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib49","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib50","first-page":"622","article-title":"Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus","volume":"32","author":"Mok","year":"2005","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib51","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.autrev.2014.12.006","article-title":"Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome","volume":"14","author":"Belizna","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.004_bib52","first-page":"780","article-title":"Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy","volume":"28","author":"Borba","year":"2001","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib53","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/0961203312450084","article-title":"Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect","volume":"21","author":"Cairoli","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.10.004_bib54","first-page":"2142","article-title":"Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus","volume":"27","author":"Tam","year":"2000","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1055\/s-0037-1613033","article-title":"Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies","volume":"87","author":"Espinola","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.10.004_bib56","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3899\/jrheum.150437","article-title":"Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy","volume":"43","author":"Durcan","year":"2016","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3899\/jrheum.120157","article-title":"Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and\/or lupus anticoagulant in systemic lupus erythematosus","volume":"40","author":"Broder","year":"2013","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort","volume":"68","author":"Kaiser","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib59","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/ard.2010.142042","article-title":"Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study","volume":"70","author":"Ruffatti","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib60","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/ard.62.11.1071","article-title":"Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus","volume":"62","author":"Doria","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib61","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3899\/jrheum.090306","article-title":"Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study","volume":"37","author":"Haque","year":"2010","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D","article-title":"Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus","volume":"42","author":"Manzi","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib63","first-page":"2137","article-title":"Natural history of hypercholesterolemia in systemic lupus erythematosus","volume":"26","author":"Bruce","year":"1999","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib64","first-page":"1264","article-title":"Lipid profiles in patients with systemic lupus erythematosus","volume":"21","author":"Leong","year":"1994","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib65","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00005792-199209000-00004","article-title":"Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices","volume":"71","author":"Petri","year":"1992","journal-title":"Med. Baltim."},{"key":"10.1016\/j.jaut.2016.10.004_bib66","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucocorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun. Rev."},{"issue":"9","key":"10.1016\/j.jaut.2016.10.004_bib67","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/art.39682","article-title":"Cumulative corticosteroids over 52 weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials","volume":"68","author":"van Vollenhoven","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib68","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.autrev.2012.03.002","article-title":"Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review","volume":"11","author":"Artenjak","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.004_bib69","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.berh.2013.07.005","article-title":"Managing lupus patients during pregnancy","volume":"27","author":"Lateef","year":"2013","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib70","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3899\/jrheum.120576","article-title":"Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study","volume":"40","author":"Del Ross","year":"2013","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib71","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1172\/JCI116396","article-title":"Prevention of fetal loss in experimental antiphospholipid syndrome by in\u00a0vivo administration of recombinant interleukin-3","volume":"91","author":"Fishman","year":"1993","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.jaut.2016.10.004_bib72","first-page":"551","article-title":"Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis","volume":"29","author":"Roberge","year":"2012","journal-title":"Am. J. Perinatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000336662","article-title":"Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis","volume":"31","author":"Roberge","year":"2012","journal-title":"Fetal Diagn. Ther."},{"key":"10.1016\/j.jaut.2016.10.004_bib74","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","author":"Andreoli","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002859.pub2","article-title":"Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant","author":"Empson","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl 3","key":"10.1016\/j.jaut.2016.10.004_bib76","first-page":"iii23","article-title":"Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers","volume":"47","author":"Erkan","year":"2008","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2016.10.004_bib77","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/rheumatology\/kep373","article-title":"Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression","volume":"49","author":"Mak","year":"2010","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2016.10.004_bib78","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/ard.2008.093179","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients","volume":"68","author":"Cervera","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib79","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/0961203307077108","article-title":"Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients","volume":"16","author":"Garc\u00eda-Carrasco","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.10.004_bib80","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1160\/TH08-06-0384","article-title":"Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort","volume":"101","author":"Neville","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.10.004_bib81","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2016.10.004_bib82","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0032-1304720","article-title":"Intensity and duration of anticoagulation therapy in antiphospholipid syndrome","volume":"38","author":"Les","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.jaut.2016.10.004_bib83","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/0961203312438116","article-title":"Obstetric and vascular APS: same autoantibodies but different diseases?","volume":"21","author":"Meroni","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.10.004_bib84","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.autrev.2011.10.016","article-title":"High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'","volume":"11","author":"Pengo","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.004_bib85","first-page":"15","article-title":"Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome","volume":"7","author":"Okuma","year":"2009","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.jaut.2016.10.004_bib86","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.2174\/092986712803306466","article-title":"Anticoagulant therapy during pregnancy for maternal and fetal acquired and inherited thrombophilia","volume":"19","author":"Giannubilo","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"10.1016\/j.jaut.2016.10.004_bib87","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/kev445","article-title":"Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome","volume":"55","author":"Sciascia","year":"2016","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2016.10.004_bib88","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.autrev.2015.03.007","article-title":"Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome","volume":"14","author":"Noel","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.004_bib89","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0961203314540968","article-title":"New oral anticoagulants in thrombotic antiphospholipid syndrome","volume":"23","author":"Chighizola","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.10.004_bib90","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/0961203315581207","article-title":"Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II\/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE","volume":"24","author":"Cohen","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.10.004_bib91","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0961203315611495","article-title":"Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial","volume":"25","author":"Pengo","year":"2016","journal-title":"Lupus"},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2016.10.004_bib92","doi-asserted-by":"crossref","first-page":"178s","DOI":"10.1097\/01.AOG.0000447195.12926.b9","article-title":"The medical management of antiphospholipid syndrome in pregnancy: a meta-analysis","volume":"123","author":"Wu","year":"2014","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jaut.2016.10.004_bib93","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0037-1612970","article-title":"Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin","volume":"87","author":"Pettila","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.10.004_bib94","first-page":"2","article-title":"Current treatment strategies for management of antiphospholipid syndrome","author":"Reggia","year":"2014","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.jaut.2016.10.004_bib95","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.1378\/chest.119.1_suppl.122S","article-title":"Use of antithrombotic agents during pregnancy","volume":"119","author":"Ginsberg","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2016.10.004_bib96","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/ar1957","article-title":"Anti-inflammatory and immunosuppressive drugs and reproduction","volume":"8","author":"Ostensen","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2016.10.004_bib97","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1182\/blood-2011-02-339234","article-title":"First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss","volume":"117","author":"Bramham","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2016.10.004_bib98","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.8755-8920.2001.450309.x","article-title":"Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin","volume":"45","author":"Vaquero","year":"2001","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.jaut.2016.10.004_bib99","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1160\/TH14-03-0191","article-title":"Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study","volume":"112","author":"Ruffatti","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jaut.2016.10.004_bib100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/03009742.2011.624117","article-title":"Physical activity in patients with systemic lupus erythematosus and matched controls","volume":"41","author":"Eriksson","year":"2012","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib101","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.ejcn.1601883","article-title":"Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects","volume":"58","author":"Remans","year":"2004","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.jaut.2016.10.004_bib102","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.10.004_bib103","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.2007.077156","article-title":"A\u00a0randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus","volume":"67","author":"Wright","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib104","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s00296-013-2811-3","article-title":"Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus","volume":"33","author":"Bello","year":"2013","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jaut.2016.10.004_bib105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/ard.2010.134817","article-title":"Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression","volume":"70","author":"Agmon-Levin","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib106","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4081\/reumatismo.2012.307","article-title":"Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease","volume":"64","author":"Piantoni","year":"2012","journal-title":"Reumatismo"},{"key":"10.1016\/j.jaut.2016.10.004_bib107","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/0961203314540966","article-title":"Correlation between serum 25(OH)D values and lupus disease activity: an original article and a systematic review with meta-analysis focusing on serum VitD confounders","volume":"23","author":"Sahebari","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.10.004_bib108","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/rheumatology\/ker352","article-title":"25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus","volume":"51","author":"Reynolds","year":"2012","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2016.10.004_bib109","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/01.STR.0000195184.24297.c1","article-title":"Reduced vitamin D in acute stroke","volume":"37","author":"Poole","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.jaut.2016.10.004_bib110","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/MAJ.0b013e31823fa7d9","article-title":"Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients","volume":"344","author":"Ravenell","year":"2012","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.jaut.2016.10.004_bib111","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(13)62388-0","article-title":"Statins: new American guidelines for prevention of cardiovascular disease","volume":"382","author":"Ridker","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.10.004_bib112","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.10.004_bib113","first-page":"2361","article-title":"Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin","volume":"33","author":"Kotyla","year":"2006","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib114","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1191\/0961203305lu2217oa","article-title":"Statins and autoimmune diseases","volume":"14","author":"Riboldi","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.10.004_bib115","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1194\/jlr.M010876","article-title":"Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis","volume":"52","author":"Tang","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jaut.2016.10.004_bib116","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1536\/ihj.14-245","article-title":"Changes of naturally occurring CD4(+)CD25(+) FOXP3(+) regulatory T cells in patients with acute coronary syndrome and the beneficial effects of atorvastatin treatment","volume":"56","author":"Wang","year":"2015","journal-title":"Int. heart J."},{"key":"10.1016\/j.jaut.2016.10.004_bib117","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/rheumatology\/kem186","article-title":"Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial","volume":"46","author":"Ferreira","year":"2007","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2016.10.004_bib118","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3402","article-title":"Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study","volume":"13","author":"Plazak","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2016.10.004_bib119","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.autrev.2015.12.007","article-title":"Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta-analysis of controlled trials","volume":"15","author":"Sahebkar","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.004_bib120","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/acr.20440","article-title":"Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Care Res. Hob."},{"key":"10.1016\/j.jaut.2016.10.004_bib121","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1749-6632.2009.04815.x","article-title":"Statins for the treatment of antiphospholipid syndrome?","volume":"1173","author":"Jajoria","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jaut.2016.10.004_bib122","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jbspin.2012.08.014","article-title":"Do all lupus patients need statins?","volume":"80","author":"Soubrier","year":"2013","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.jaut.2016.10.004_bib123","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2010.136762","article-title":"Lupus atherosclerosis prevention study (LAPS)","volume":"70","author":"Petri","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib124","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.004_bib125","first-page":"409","article-title":"Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin","volume":"30","author":"Sciascia","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2016.10.004_bib126","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A\u00a0pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib127","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/TP.0000000000000267","article-title":"A\u00a0case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab","volume":"98","author":"Bakhtar","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.jaut.2016.10.004_bib128","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"10.1016\/j.jaut.2016.10.004_bib129","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/art.22018","article-title":"Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients","volume":"54","author":"Bucciarelli","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib130","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.10.004_bib131","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2016.10.004_bib132","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2005.11.034","article-title":"Long-term prognosis and causes of death in systemic lupus erythematosus","volume":"119","author":"Doria","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jaut.2016.10.004_bib133","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/ard.2010.130476","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs","volume":"69","author":"Bertsias","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.10.004_bib134","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ajkd.2003.09.011","article-title":"Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis","volume":"43","author":"Moroni","year":"2004","journal-title":"Am. J. Kidney Dis."},{"issue":"12","key":"10.1016\/j.jaut.2016.10.004_bib135","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1177\/0961203316637431","article-title":"The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus","volume":"25","author":"Taraborelli","year":"2016","journal-title":"Lupus"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116302475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116302475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:14:32Z","timestamp":1760256872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841116302475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":135,"alternative-id":["S0896841116302475"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2016.10.004","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The antiphospholipid syndrome in patients with systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}